Bone Marrow Dosimetric Analysis of Lymphopenia in Patients With Esophageal Squamous Cell Carcinoma Treated With Chemoradiotherapy

Qian Wang
Shandong University

Qingtao Qiu
Shandong Tumor Hospital and Institute

Zicheng Zhang
Shandong Tumor Hospital and Institute

Jing Zhang
Shandong University

Guanghui Yang
Shandong University

Chengxin Liu
Shandong Tumor Hospital and Institute

Baosheng Li (bsli@sdfmu.edu.cn)
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China

Research

Keywords: Esophageal Cancer, Lymphocytes, Chemoradiotherapy, Bone Marrow

DOI: https://doi.org/10.21203/rs.3.rs-66132/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Lymphocytes as a marker of immune function are essential to the immune response. Sternum and vertebra bone marrow (BM) exposed to radiation may affect lymphocytes during radiotherapy (RT) for esophageal carcinoma (EC). We analyzed the relationship among peripheral blood lymphocytes, exposed sternum and vertebra body BM, and overall survival (OS) to find BM dosimetric parameters of lymphopenia during chemoradiotherapy (CRT) for patients with esophageal squamous cell carcinoma (ESCC).

**Methods:** We examined 476 ESCC patients from January 2012 to January 2015, all of whom received concurrent or sequential CRT. Absolute lymphocyte counts (ALC) during RT of each patient were collected from the routine workup at the following RT times: pretreatment ALC (ALC0), at 1–5, 6–10, 11–15, 16–20, and 21–25, and more than 26 sessions (called ALC1–6, respectively). The sternum and vertebral body BM were delineated in accordance with uniform standards, and the irradiated volumes were calculated by dose-volume histograms (DVH). The Kaplan–Meier method and Cox proportional hazards regression were used to analyze the survival of the patients. Comparisons of DVH were performed using the Mann–Whitney U test or two-sample t-test where appropriate.

**Results:** A relative volume of sternum BM irradiated by more than 20 Gy could clearly affect the peripheral blood lymphocytes. The V20 of sternum BM and V50 of vertebra body BM were related to the OS of the patients, and the level of ALC2 (at 6–10 times of RT) could predict the patients’ outcomes. The Cox regression analyses showed that the 218 patients with ALC2 ≥ 0.8×10^9/L had a significantly longer OS (47.0 vs. 30.9, p<0.0001) than the 258 patients with ALC2 < 0.8×10^9/L.

**Conclusion:** In patients with ESCC, the relative volume of sternum BM irradiated by more than 20 Gy was associated with lymphocyte. The V20 of the sternum BM and the V50 of the vertebra body BM were related to the OS of the patients. The level of ALC2 is a significant prognostic factor in esophageal carcinoma patients.

**Background**

Esophageal cancer (EC) is the eighth most common cancer worldwide and is the sixth most common cause of death from cancer[1]. At present, neoadjuvant chemoradiotherapy (CRT) and radical concurrent CRT are the standard treatment of patients with advanced EC. Although these treatment methods have improved the overall survival (OS) rate relative to traditional treatments, they have also increased the occurrence of acute toxic effects[2], and the 5-year survival rate is still less than 30–40%.

Studies of immunotherapy, such as KEYNOTE-181 and ATTRACTION-3, have shown it to be superior to chemotherapy in advanced EC, so research on the immune system is the key to further prolonging the survival rate of the patients. Lymphocytes as the primary mediators of cellular immunity in the human body are effective indicators in clinical work-ups that reflect the immune function of patients with cancer. The occurrence, development and prognosis of tumors are closely related to the immune function. When the immune function declines, tumor cells will escape the immune surveillance of the immune system and form solid tumors. However, ionizing radiation during radiotherapy (RT) will not only kill tumor cells, but will also have a killing and inhibitory effect on normal lymphocytes, which indirectly interferes with the anti-tumor process and affects the prognosis of the patients.
Previous studies have shown that lymphopenia induced by radiation (LIR) can be used as a predictor of a poor outcome for many types of tumors, such as non-small-cell lung cancer, pancreatic cancer, breast cancer, glioma, and head and neck cancer\cite{3-7}. As we all know, LIR is related to bone marrow suppression. Bone marrow (BM), as the main site of lymphocyte generation, is very sensitive to radiation. In the process of treating EC patients with RT, the sternum and thoracic vertebra BM will inevitably be exposed to different doses of radiation as the target area changes. The hematopoiesis of the sternum and vertebral body BM accounts for 30% of the entire amount, so the generation of lymphocytes will be affected. In similar studies in the past, patients with cervical cancer who received low doses of pelvic BM (V10 $\geq$ 90%) had a higher incidence of leukopenia and neutropenia than those who received BM V10 <90\%\cite{8}. In addition, the mean dose and low-dose radiation parameters (V5, V10, V15, V20) of whole bone or bone cavities of the lumbosacral spine were found to be correlated most significantly with HT3+ for squamous cell carcinoma of the anal canal\cite{9}.

Based on the previous findings described above, this study aimed to explore the relationships between the exposure of the sternum and vertebra body BM to radiation to the lymphocytes and OS of EC patients to find dosimetric predictors of lymphopenia during CRT for patients with ESCC.

**Methods**

**Patients and clinical data**

This article is a retrospective study. Patients with histologically confirmed ESCC who received CRT at Shandong Cancer Hospital Affiliated to Shandong First Medical University between January 2012 and January 2015 were considered to be eligible. Considering the EC staging criteria have slight differences in recent years, we reclassified the disease stage of the patients according to the eighth edition of the American Joint Committee on Cancer's Cancer Staging Manual. Inclusion criteria: 1. KPS $\geq$ 70, pathologically confirmed patients with ESCC who received CRT; 2. No other tumors, no previous history of chemotherapy or RT; 3. Survival period greater than 6 months; 4. Normal blood cell level before treatment, no other immune diseases, no immune related drugs (suppression or enhancement). Exclusion criteria: 1. Patients with incomplete case data who could not be reclassified as to disease stage; 2. The total dose of RT did not reach the established radical dose; 3. A lack of blood routine results during RT $\geq$ 2 times; 4. Poor physical condition with severe underlying disease; 5. Chronic inflammatory or autoimmune disease; 6. Blood transfusion within the last 3 months.

We collected the following information from all of the patients: age, sex, KPS, tumor location, tumor length, differentiation, and TNM stage. The absolute value of lymphocytes (ALC) was collected within 1 week of starting RT, and then at 1–5, 6–10, 11–15, 16–20, 21–25, and more than 26 sessions of RT (referred to as ALC0, ALC1–6, respectively). One missing value was allowed during the whole treatment. Meanwhile, we also obtained the maximum, minimum, rate of decline, and the average value of lymphocytes. After the entire treatment was completed, the patients were followed-up every 2 months for half a year. If their condition was stable, the follow-up time was prolonged to every 3–6 months, and the overall follow-up was for at least 5 years. The study endpoints were overall survival (OS) (time from the end of the treatment to death from any cause or the last follow-up time).
Radiotherapy and Chemotherapy

The target of RT was delineated on the eclipse system as follows. Gross Tumor Volume (GTV): Combined with CT/PET-CT or titanium clip markers under the endoscope to identify the primary tumors and positive lymph node areas; clinical Target Volume (CTV): Add the high-risk areas of lymphatic drainage on the basis of GTV; Planning Target Volume (PTV): 0.8 cm was added in the horizontal directions and 3 cm expansion in the axial direction to account for setup uncertainty and organ motion. Radiation dose: 50–60 Gy (delivered in 25–33 fractions of 1.8–2.0 Gy/fraction). Normally endangered organs: total lung V20 ≤35%, V5 ≤65%, Dmean ≤20 Gy; heart Dmean ≤35 Gy; spinal cord Dmax ≤45 Gy. In addition, all patients received platinum-based chemotherapy with paclitaxel or fluorouracil every 21–28 days. The chemotherapy drugs were given according to the standard dose. Concurrent CRT means chemotherapy drugs at intervals of 21–28 days were given at the beginning of RT. Nonconcurrent CRT was mainly sequential and induction CRT.

Delineation of sternum and vertebra body BM

We transferred the CT images of all of the patients to the MIM(6.8.2) system, and the delineation process was completed on mediastinal window. Considering that the hematopoietic site of adults is mainly in the BM cavity, we declined the BM according to the following criteria shown in (Fig. 1). Sternum BM: 1. upper boundary is the sternum notch, lower boundary is the xiphoid process, the circumference is the junction with the bone; 2. due to the sternum angle being indistinguishable from the surrounding costal cartilage, the delineation of this area was done under the guidance of two imaging physicians. Vertebral body BM: 1. upper and lower bounds are the projection range of the 10% isodose line of PTV on the vertebrae, and the circumference is the junction with the bone; 2. avoid delineation of intervertebral discs and pyramidal attachments based on the continuity and anatomical structure of the spine.

Statistical analysis

The characteristics of the patients were described by descriptive statistics. Survival was estimated by the Kaplan–Meier method and survival curve comparisons were performed using the log-rank test. The relationship between clinical characteristics of the patients and OS were tested by Cox proportional hazards regression. Propensity score matching was used to compensate for the differences in baseline characteristics. The cutoff value of the lymphocytes was obtained by X-tile software. Chi-square tests were used to analyze the differences between different groups. Comparisons of DVH were performed using the Mann–Whitney U test or two-sample t-test, where appropriate. All statistical analyses were performed using Statistical Package for the Social Sciences, SPSS software 22.0, and P < 0.05 was considered to be significant.

Results

Basic characteristics

After 5 years of follow-up, 476 patients were recruited into this study, including 367 men and 109 women. As shown in Table 1 the median age of all patients was 63, and 64.5% were over 60 years. Phase I and II, III, and IV were administered to 11.3, 61.6, and 27.1% of the patients, respectively. Phase I and II patients were given CRT treatment due to the following reasons: contraindicated for surgery due to a poor physical condition (11
patients), cervical EC (16 patients) and refusal of surgery (27 patients). Only 12.2% of patients were treated with concurrent CRT, while 87.8% had nonconcurrent CRT. The average cycle of chemotherapy was 4.2, and the average dose of RT was 59.3 Gy. Most patients (65.8%) were treated with intensity-modulated radiation therapy (IMRT). The median OS of the patients was 28.4 months, and the 1-year, 3-year, and 5-year OS rates were 82.1%, 32.8% and 3.8%, respectively.

**Correlation between basic clinicopathological characteristics and OS**

The correlations between the basic clinicopathological characteristics and OS were analyzed by COX regression model, and (Karnofsky Performance Status)KPS (p=0.011), TNM staging (p<0.0001), ALC2 (6–10 sessions of RT) (p=0.025), and the pretreatment cyfra level (p=0.002) had a statistical correlation with OS (Table 1). On the other hand, there was no significant correlation between OS and chemotherapy, minimum value of lymphocytes, the maximum value of ALC, the drop rate, ALC0,1,3–6, sex, age, RT dose, or RT technique (p>0.05). We obtained the ALC2 cutoff value (0.8×10^9/L) using X-tile. All patients were divided into two groups: less than 0.8×10^9/L group (group 1) and the greater than or equal to 0.8×10^9/L group (group 2). The patients in group 1 were matched 1:1 to the patients in group 2 according to their propensity score using the global optimum method; 55 pairs of patients were matched finally.

**Correlation between the sternum and vertebral body BM and OS**

The dose-relative/absolute volume histograms of all patients could be obtained after drawing the sternum and vertebral body BM according to the criteria mentioned above. The results shown in Table 2 were obtained by using Cox proportional hazard model: the relative and absolute V20 of the sternum BM were both statistically correlated with OS (p=0.044; p=0.027), and the relative and absolute V50 of the vertebra body BM were also statistically correlated with OS (p=0.027; p=0.024).

**Comparison of the differences between the two groups**

Group 1 showed a significantly inferior overall median survival compared with group 2 (30.9 vs. 47.0 months, p<0.0001) (Fig. 2). After matching for the other confounding factors, the median OS of the two groups were 35.5 vs. 49.8 months (p = 0.001). In Table 3, we can see there were significant differences between the two groups for tumor location, RT pattern, chemotherapy, and cyfra level before treatment (p<0.05). On further analysis of the tumor location, we found that middle and lower thoracic EC were more likely to be associated with a decrease in peripheral blood lymphocytes than cervical EC (Fig. 3).

**Relationship between the sternum and vertebra body BM and lymphocytes**

To analyze the relationship between the sternum and vertebra body BM and lymphocytes, we compared the differences of exposed BM between the two groups of patients divided according to the cutoff value of the lymphocytes. After propensity score matching (Fig. 4), it was concluded that there was a significant difference in the relative volume of the sternum BM irradiated by more than 20 Gy between the two groups (p<0.05), but there was no significant difference for vertebral body BM (p>0.05)(Table 4).

**Discussion**
The results of this study indicated that the relative volume of sternum BM irradiated by more than 20 Gy could obviously affect the peripheral blood lymphocytes. The V20 of the sternum BM and the V50 of the vertebra body BM were related to the OS of the patients, and the level of ALC2 could predict the outcomes of the patients. Based on these findings, we suggest that in clinical work, while ensuring the target treatment dose of patients with ESCC, the V20 of the sternum BM and the V50 of the vertebra body BM should be reduced as much as possible, so that the peripheral blood lymphocytes of the patients are less affected by ionizing radiation, which may be ultimately beneficial to improve the therapeutic efficacy of the RT and the survival of the patients.

During this study, 350 patients suffered leukopenia during treatment, clinically treated with Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) Injection. Considering the half-life of rhG-CSF is 3.5 hours, and its effect was mainly on myeloid system but weaker effect on lymphatic system, so we collected ALC after injecting rhG-CSF 24 hours to avoid this influence. Some previous studies have reported lymphocytes are correlated with the prognosis of patients. Deng et al. demonstrated that significant G4 lymphopenia (<200 cells/mL) during CRT was an independent predictor of survival outcomes of patients with EC [10]. The minimum ALC may be a prognostic factor indicating a worse outcome for nasopharyngeal cancer and hepatocellular carcinoma [11, 12]. Pretreatment lymphopenia is a predictor of a good outcome as well as a predictive factor for tumor response and chemotherapy-related hematological toxicity in metastatic ESCC [13]. Likewise, in patients with ESCC treated with CRT, we found that ALC2 can predict the patients’ outcomes. Furthermore, middle and lower thoracic EC were more likely to cause a decrease in peripheral blood lymphocytes than cervical EC. This result is consistent with previous studies [10] and is probably because the heart and spleen are greatly affected by RT during the treatment of middle and lower thoracic EC. As the distal esophageal location passes across the heart, a significant pool of lymphocytes will be exposed to radiation treatment for distal esophageal tumors [14]. Yue et al. showed that higher spleen irradiation doses were significantly correlated with a lower Min ALC during RT for hepatocellular carcinoma [15].

We found that the relative volume of sternum BM irradiated by more than 20 Gy could obviously affect the peripheral blood lymphocytes in patients with ESCC. Miyoshi N et al. have shown that BM chemical toxicity is an important prognostic factor in patients with T4 EC who underwent radical resection after CRT [16]. The sternum volume exposure to 50 Gy contributed to the BM suppression in breast cancer [17]. Low-dose radiation to the pelvis was also significantly associated with hematotoxicity in patients with pelvic tumors, such as cervical cancer and rectal squamous cell carcinoma [8, 18]. However, WU et al. reported that radiation doses to the thoracic vertebrae and ribs in esophageal cancer patients treated with neoadjuvant CRT, including the average dose and the V5–30 of the thoracic vertebrae, and the average dose and V5–20 of the ribs, were related to lymphopenia of grade 3 or above. However, the exposure to the sternum, scapular and clavicular BM did not affect the occurrence of hematotoxicity [19]. The reasons for these different results may be due to differences in patient inclusion criteria, treatment mode, statistical methods and so on.

According to the existing studies, the effect of ionizing radiation on BM is related to the BM microvascular system. Weintraub NL et al. definitively showed a causal relationship between radiation and vascular diseases [20]. After the BM microvessels are exposed to ionizing radiation, not only is the blood supply of the BM interrupted but also other normal physiological functions may be negatively affected directly or indirectly. In a study by Slayton et al., mice were lethally irradiated with 9.5 Gy and a week after irradiation they lost
homeostasis between the extravascular and intravascular space within the BM. BM sinusoidal dilations with unusual shapes and hemorrhages within the BM of irradiated mice were also detected[21]. In our study, we found that the level of ALC2 could predict the outcomes of the patients, which may be due to the damage of the BM microvascular system caused by the cumulative dose of radiation after 6–10 sessions. At this time point, the level of lymphocytes can better reflect the immune capacity of each patient, which could affect the prognosis of the patients. However, the abovementioned studies are all preclinical studies, and further clinical studies are needed to support this conclusion.

There are several limitations of this study: 1. All data were derived from a retrospective cohort and we could not standardize the times of blood testing during patient treatment; 2. Limited by its sample size, the current data are not generally representative; 3. There are no standard criteria for delineating BM ranges and different delineation methods may affect the final results. However, this is the first comprehensive retrospective study on the relationships among lymphocyte levels, survival rate and the sternum and vertebral body BM in patients with unresectable ESCC. Therefore, these results still need to be confirmed in large-scale prospective studies in the future.

**Conclusions**

In patients with ESCC, the relative volume of sternum BM irradiated by more than 20 Gy was associated with lymphocyte. The V20 of the sternum BM and the V50 of the vertebra body BM were related to the OS of the patients. The level of ALC2 is a significant prognostic factor in esophageal carcinoma patients.

**Abbreviations**

BM: bone marrow; RT: radiotherapy; EC: esophageal cancer; OS: overall survival; CRT: chemoradiotherapy; ESCC: esophageal squamous cell carcinoma; ALC: absolute value of lymphocytes; DVH: dose-volume histograms; LIR: lymphopenia induced by radiation; GTV: gross tumor volume; CTV: clinical tumor volume; PTV: planning target volume; KPS: Karnofsky Performance Status; IMRT: Intensity-modulated radiation therapy; S1: sternum of group1; S2: sternum of group2; V1: vertebra body of group1; V2: vertebra body of group2

**Declarations**

**Ethics approval and consent to participate:** The study was conducted in agreement with the Declaration of Helsinki. All the patients signed a consent to share their clinical data and information for clinical studies.

**Consent for publication:** Not applicable

**Availability of data and materials:** The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Competing interests:** The authors declare that they have no competing interests
This study was supported by National Nature Science Foundation of China (Grant No. 81874224), Provincial Key Research and Development Program of Shandong (Grant No. 2017CXZC1206), and Tumor prevention and control Joint Fund of Shandong province natural science fund (ZR2019LZL008).

Authors' contributions: QW designed the study and drafted the manuscript. QTQ, ZCZ, GHY and JZ gave the help of statistical analysis. BSL and CXL coordinated, edited, and finalized the drafting of manuscript. All authors read and approved the final manuscript.

Acknowledgements: Not applicable.

Authors' details:

1. Cheeloo College of Medicine, Shandong University, Jinan, China

2. Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China

References

1. Ferlay Jacques, Soerjomataram Isabelle, Dikshit Rajesh et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. [J]. Int. J. Cancer, 2015, 136: E359-86.

2. Li-Li Z, Ling Y, Hui W, et al. A Meta-Analysis of Concurrent Chemoradiotherapy for Advanced Esophageal Cancer [J]. Plos One, 2015, 10(6): e0128616-

3. Tang C, Liao Z, Gomez D, et al. Lymphopenia Association With Gross Tumor Volume and Lung V5 and Its Effects on Non-Small Cell Lung Cancer Patient Outcomes [J]. International Journal of Radiation Oncology*Biology*Physics, 2014, 89(5):1084-1091.

4. Balmanoukian A, Ye X, Herman J, et al. The Association Between Treatment-Related Lymphopenia and Survival in Newly Diagnosed Patients with Resected Adenocarcinoma of the Pancreas [J]. Cancer Investigation, 2012, 30(8):571-576.

5. Sun G, Wang S, Song Y, et al. Radiation-Induced Lymphopenia is Associated with Radiation Fractionation and Predicts Poorer Prognosis in Patients with Breast Cancer [J]. International Journal of Radiation Oncology*Biology*Physics, 2019, 105(1):E46.

6. Kim W J, Dho Y S, Ock C Y, et al. Clinical observation of lymphopenia in patients with newly diagnosed glioblastoma [J]. Journal of Neuro Oncology, 2019.

7. Campian J L, Sarai G, Ye X, et al. Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer [J]. Head & Neck, 2014, 36(12):1747-1753.

8. Loren, K, Mell, et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy [J]. International Journal of Radiation Oncology*Biology*Physics, 2006.

9. Cheng Jason Chia-Hsien, Bazan Jose G, Wu Jian-Kuen et al. Lumbosacral spine and marrow cavity modeling of acute hematologic toxicity in patients treated with intensity modulated radiation therapy for
squamous cell carcinoma of the anal canal.[J]. Pract Radiat Oncol, 2014, 4: 198-206.

10. Deng W, Xu C, Liu A, et al. The relationship of lymphocyte recovery and prognosis of esophageal cancer patients with severe radiation-induced lymphopenia after chemoradiation therapy[J]. Radiotherapy & Oncology, 2019, 133:9-15.

11. Zhao Q, Xu X, Yue J, et al. Minimum absolute lymphocyte counts during radiation are associated with a worse prognosis in patients with unresectable hepatocellular carcinoma[J]. Therapeutic Advances in Gastroenterology, 2017, 10(2):231-241.

12. Oyeon, Cho, MD, et al. Minimum absolute lymphocyte count during radiotherapy as a new prognostic factor for nasopharyngeal cancer[J]. Head & Neck,

13. Kou F, Lu Z, Li J, et al. Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first-line chemotherapy[J]. Cancer Medicine, 2016, 5(5):778-786.

14. Davuluri R, Jiang W, Fang P, et al. Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy.[J]. int j radiat oncol biol phys, 2017, 99(1):128-135.

15. Liu J, Zhao Q, Deng W, et al. Radiation-related lymphopenia is associated with spleen irradiation dose during radiotherapy in patients with hepatocellular carcinoma[J]. Radiation Oncology, 2017, 12(1):90.

16. Miyoshi N. Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer[J]. J Surg Oncol, 2009, 99.

17. Wang Q, Ye T, Chen HL, et al. Correlation between intensity modulated radiotherapy and bone marrow suppression in breast cancer.[J]. european review for medical & pharmacological sciences, 2016, 20(1):75.

18. Bazan Jose G,Luxton Gary,Mok Edward C et al. Normal tissue complication probability modeling of acute hematologic toxicity in patients treated with intensity-modulated radiation therapy for squamous cell carcinoma of the anal canal.[J]. Int. J. Radiat. Oncol. Biol. Phys., 2012, 84: 700-6.

19. Lee Jie,Lin Jhen-Bin,Sun Fang-Ju et al. Dosimetric predictors of acute haematological toxicity in oesophageal cancer patients treated with neoadjuvant chemoradiotherapy.[J]. Br J Radiol, 2016, 89: 20160350.

20. Neal L Weintraub. Understanding Radiation-Induced Vascular DiseaseEditorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.[J]. Journal of the American College of Cardiology, 2000, 35(6):1577-9.

21. Slayton W B, Li X M, Butler J, et al. The Role of the Donor in the Repair of the Marrow Vascular Niche Following Hematopoietic Stem Cell Transplant[J]. Stem Cells, 2007, 25(11):2945-2955.

Tables

Table 1. Relationship between basic clinicopathological characteristics of patients and OS
| Characteristics                                      | Number (%) (Total patients = 476) | P value  |
|-----------------------------------------------------|-----------------------------------|----------|
| Age(median (range))                                 | 63(37-85)                         |          |
| Age<60 vs. ≥60                                      | 169 (35.5) vs. 307(64.5)          | 0.186    |
| Gender (male vs. female)                            | 367 (77.1) vs. 109(22.9)          | 0.141    |
| KPS 70 vs. 80 vs. 90                                | 15(3.2) vs. 235(49.4) vs. 226(47.5) | 0.011    |
| Tumor location (upper vs. middle vs. lower)         | 196(41.2) vs. 205(43.1) vs. 75(15.8) | 0.245    |
| TNM I vs. III vs. IV                                | 54(11.3) vs. 293(61.6) vs. 129(27.1) | <0.0001  |
| RT-technology (IMRT vs. CRT)                        | 313(65.8) vs. 163(34.2)           | 0.232    |
| Dose(50 group vs. 60 group)                         | 74 (15.5) vs. 402(84.5)           | 0.828    |
| RT-pattern (Concurrent vs. Non-concurrent)          | 58(12.2) vs. 418(87.8)            | 0.173    |
| Chemotherapy-Paclitaxel group vs. 5-FU group        | 276 vs. 200                       | 0.734    |
| Chemotherapy cycle 1~2 vs. 3~4 vs. 5~6 vs.>6        | 104(24.2) vs. 183(38.9) vs. 143(37.0) vs. 46(9.7) | 0.154    |
| ALC0                                                |                                  | 0.636    |
| ALC1                                                |                                  | 0.261    |
| ALC2                                                |                                  | 0.025    |
| ALC3                                                |                                  | 0.961    |
| ALC4                                                |                                  | 0.325    |
| ALC5                                                |                                  | 0.112    |
| ALC6                                                |                                  | 0.978    |
| CEA before treatment                                |                                  | 0.204    |
| Cyfra before treatment                              |                                  | 0.002    |

**Abbreviations:** KPS Karnofsky Performance Status, RT radiotherapy, IMRT Intensity-modulated radiation therapy, CRT chemoradiotherapy, ALC absolute value of lymphocytes

**Table 2.** Relationship between dose-relative volume of BM and OS
| Parameters  | HR(CI 95%) | P value |
|------------|------------|---------|
| RV5Gy      |            |         |
| sternum    | 1.05(0.90-1.21) | 0.515 |
| vertebra body | 0.92(0.68-1.25) | 0.594 |
| RV10Gy     |            |         |
| sternum    | 0.96(0.85-1.09) | 0.581 |
| vertebra body | 1.10(0.87-1.40) | 0.414 |
| RV15Gy     |            |         |
| sternum    | 1.12(0.99-1.26) | 0.051 |
| vertebra body | 1.02(0.81-1.29) | 0.878 |
| RV20Gy     |            |         |
| sternum    | 0.92(0.86-0.99) | 0.044 |
| vertebra body | 0.99(0.79-1.25) | 0.950 |
| RV25Gy     |            |         |
| sternum    | 1.03(0.97-1.09) | 0.414 |
| vertebra body | 0.97(0.83-1.13) | 0.680 |
| RV30Gy     |            |         |
| sternum    | 1.01(0.96-1.06) | 0.652 |
| vertebra body | 1.05(0.92-1.20) | 0.482 |
| RV35Gy     |            |         |
| sternum    | 0.97(0.93-1.01) | 0.122 |
| vertebra body | 0.99(0.92-1.06) | 0.731 |
| RV40Gy     |            |         |
| sternum    | 1.03(0.99-1.07) | 0.178 |
| vertebra body | 0.99(0.94-1.04) | 0.675 |
| RV45Gy     |            |         |
| sternum    | 0.99(0.95-1.02) | 0.463 |
| vertebra body | 0.97(0.91-1.02) | 0.233 |
| RV50Gy     |            |         |
| sternum    | 1.01(0.99-1.04) | 0.428 |
| vertebra body | 1.04(1.00-1.08) | 0.027 |

Relationship between dose-relative volume of BM and OS
| Parameters | HR(CI 95%)       | P value |
|-----------|-----------------|---------|
| AV5Gy     | sternum 1.00(0.78-1.29) | 0.991   |
|           | vertebra body 0.92(0.70-1.21) | 0.554   |
| AV10Gy    | sternum 0.84(0.47-1.53) | 0.575   |
|           | vertebra body 1.09(0.70-1.69) | 0.716   |
| AV15Gy    | sternum 1.66(0.90-3.04) | 0.102   |
|           | vertebra body 0.99(0.66-1.49) | 0.966   |
| AV20Gy    | sternum 0.59(0.37-1.94) | 0.027   |
|           | vertebra body 1.06(0.72-1.54) | 0.781   |
| AV25Gy    | sternum 1.34(0.95-1.91) | 0.100   |
|           | vertebra body 0.91(0.72-1.15) | 0.430   |
| AV30Gy    | sternum 0.97(0.77-1.24) | 0.823   |
|           | vertebra body 1.10(0.91-1.33) | 0.329   |
| AV35Gy    | sternum 0.86(0.72-1.03) | 0.102   |
|           | vertebra body 0.99(0.90-1.10) | 0.826   |
| AV40Gy    | sternum 1.18(0.99-1.38) | 0.053   |
|           | vertebra body 0.97(0.90-1.04) | 0.381   |
| AV45Gy    | sternum 0.90(0.76-1.06) | 0.192   |
|           | vertebra body 0.96(0.89-1.04) | 0.284   |
| AV50Gy    | sternum 1.04(0.94-1.14) | 0.440   |
|           | vertebra body 1.06(1.01-1.11) | 0.024   |

**Abbreviations:** BM bone marrow, OS overall survival, HR hazard ratio, RVxGy relative volume irradiated by xGy, AVxGy absolute volume irradiated by xGy

**Table 3.** Comparative analysis of patient clinicopathological characteristics from unmatched and propensity-matched groups
| Characteristic         | Before matching |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
|-----------------------|----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                       | LC<0.8(n=258) (%) | LC≥0.8(n=218) (%) | P value | LC<0.8(n=55) (%) | LC≥0.8(n=55) (%) | P value |                  |                  |                  |                  |                  |
| Age(average)          | 61.8           | 62.5            | 0.0971          | 63.8            | 63.0            | 1                |                  |                  |                  |                  |                  |
| Age<60                | 97(20.4)       | 72(15.1)        | 16(14.5)        | 16(14.5)        |                  |                  |                  |                  |                  |                  |                  |
| Age≥60                | 161(33.8)      | 146(30.7)       | 39(35.5)        | 39(35.5)        |                  |                  |                  |                  |                  |                  |                  |
| Gender                |                | 0.500           |                  | 0.654           |                  |                  |                  |                  |                  |                  |                  |
| Male                  | 202(42.4)      | 165(34.7)       | 41(37.3)        | 43(39.1)        |                  |                  |                  |                  |                  |                  |                  |
| Female                | 56(11.8)       | 53(11.1)        | 14(12.7)        | 12(10.9)        |                  |                  |                  |                  |                  |                  |                  |
| KPS                   |                | 0.124           |                  | 0.615           |                  |                  |                  |                  |                  |                  |                  |
| 70                    | 10(2.1)        | 5(1.1)          | 2(1.8)          | 3(2.7)          |                  |                  |                  |                  |                  |                  |                  |
| 80                    | 136(28.6)      | 99(20.8)        | 31(28.2)        | 26(23.6)        |                  |                  |                  |                  |                  |                  |                  |
| 90                    | 112(23.5)      | 114(23.9)       | 22(20.0)        | 26(23.6)        |                  |                  |                  |                  |                  |                  |                  |
| Tumor location        | <0.0001        |                  |                  | 0.496           |                  |                  |                  |                  |                  |                  |                  |
| Upper(cervical and upper thoracic) | 92(19.3) | 104(21.8) | 21(19.1) | 20(18.2) |                  |                  |                  |                  |                  |                  |                  |
| Middle thoracic       | 119(25.0)      | 86(18.1)        | 23(20.9)        | 28(25.5)        |                  |                  |                  |                  |                  |                  |                  |
| Lower thoracic        | 47(9.9)        | 28(5.9)         | 11(10.0)        | 7(6.4)          |                  |                  |                  |                  |                  |                  |                  |
| Tumor length Length(cm) |                | 0.634           |                  | 0.603           |                  |                  |                  |                  |                  |                  |                  |
| 1-5                   | 167(35.1)      | 138(29.0)       | 37(33.6)        | 38(34.5)        |                  |                  |                  |                  |                  |                  |                  |
| 5.1-10                | 84(17.6)       | 77(16.2)        | 17(15.5)        | 17(15.5)        |                  |                  |                  |                  |                  |                  |                  |
| 10.1-15               | 6(1.3)         | 2(0.4)          | 1(0.9)          | 0               |                  |                  |                  |                  |                  |                  |                  |
| 15.1-20               | 1(0.2)         | 1(0.2)          | 0               | 0               |                  |                  |                  |                  |                  |                  |                  |
| TNM                   |                | 0.224           |                  | 0.699           |                  |                  |                  |                  |                  |                  |                  |
| III                   | 29(6.1)        | 25(5.3)         | 6(5.5)          | 7(6.4)          |                  |                  |                  |                  |                  |                  |                  |
| III                   | 149(31.3)      | 144(30.3)       | 40(36.4)        | 36(32.7)        |                  |                  |                  |                  |                  |                  |                  |
|        |        |        |        |        |
|--------|--------|--------|--------|--------|
| IV     | 80(16.8)| 49(10.3)| 9(8.2) | 12(10.9)|
| cTstage| 0.105  | 0.823  |        |        |
| T1&T2   | 29(6.1) | 22(4.6) | 5(4.5) | 6(5.5) |
| T3     | 175(36.8)| 150(31.5)| 40(36.4)| 37(33.6)|
| T4     | 54(11.3) | 46(9.7) | 10(9.1) | 12(10.9)|
| cNstage| 0.951  | 0.792  |        |        |
| N0     | 35(7.4) | 30(6.3) | 9(8.2) | 8(7.3) |
| N+     | 223(46.8)| 188(39.5)| 46(41.8)| 47(42.7)|
| RT-technology | 0.946 | 1 |        |        |
| IMRT   | 170(35.7)| 143(30.0)| 34(30.9)| 34(30.9)|
| CRT    | 88(18.5) | 75(15.8) | 21(19.1) | 21(19.1) |
| Dose(Gy) | 0.463 | 0.376 |        |        |
| 50 group | 43(9.0) | 31(6.5) | 8(7.3) | 5(4.5) |
| 60 group | 215(45.2)| 187(39.3)| 47(42.7)| 50(45.5)|
| RT-pattern | 0.036 | 0.808 |        |        |
| Concurrent | 24(5.0) | 34(7.1) | 45(40.9)| 44(40.0)|
| Non-concurrent | 234(49.2)| 184(38.7)| 10(9.1)| 11(10.0)|
| Chemotherapy | 0.024 | 0.251 |        |        |
| Paclitaxel+ | 166(34.9)| 118(24.8)| 22(20.0)| 28(25.5)|
| 5-FU+   | 92(19.3) | 100(21.0)| 33(30.0)| 27(24.5)|
| Chemotherapy cycle | 0.658 | 0.763 |        |        |
| 1~2    | 55(11.6) | 49(10.3) | 16(14.5)| 13(11.8)|
| 3~4    | 94(19.7) | 89(18.7) | 21(19.1)| 21(19.1)|
| 5~6    | 82(17.2) | 61(12.8) | 18(16.4)| 21(19.1)|
|                | >6             | ≥1.6           | <1.6           | ≥6.4           |
|----------------|----------------|----------------|----------------|----------------|
|                | 27(5.7)        | 19(4.0)        | 61(12.8)       | 223(46.8)      |
|                |                |                | 48(10.1)       | 203(42.6)      |
|                |                |                | 13(11.8)       | 49(44.6)       |
|                |                |                | 11(10.0)       | 52(47.3)       |
|                | 0              | 42(38.2)       | 197(41.4)      | 35(7.4)        |
|                |                |                | 170(35.7)      | 15(3.2)        |
|                |                |                |                | 6(5.4)         |
|                |                |                |                | 3(2.7)         |
| **Differentiation**  | **0.317**      | **0.915**      | **0.674**      | **0.018**      |
| **hyper**       | 18(3.8)        | 23(4.8)        | 4(3.6)         | 5(4.5)         |
| **Middle**      | 25(5.3)        | 24(5.0)        | 8(7.2)         | 7(6.3)         |
| **lower**       | 215(45.2)      | 171(35.9)      | 43(39.1)       | 43(39.1)       |

**Abbreviations:** KPS Karnofsky Performance Status, RT radiotherapy, IMRT Intensity-modulated radiation therapy, CRT chemoradiotherapy, LC lymphocytes, ALC absolute value of lymphocytes

**Table 4.** Relative volume of sternum, vertebra body BM between the two groups
| Parameters | Relative volume | P value |
|------------|----------------|---------|
| RV5Gy S1 vs. S2 | 96.5 vs. 95.0 | 0.221 |
| V1 vs. V2 | 99.9 vs. 99.6 | 0.488 |
| RV10Gy S1 vs. S2 | 94.0 vs. 93.7 | 0.134 |
| V1 vs. V2 | 99.0 vs. 99.2 | 0.859 |
| RV15Gy S1 vs. S2 | 86.5 vs. 90.0 | 0.094 |
| V1 vs. V2 | 95.6 vs. 97.5 | 0.699 |
| RV20Gy S1 vs. S2 | 83.5 vs. 85.0 | 0.033 |
| V1 vs. V2 | 94.0 vs. 95.5 | 0.734 |
| RV25Gy S1 vs. S2 | 75.0 vs. 75.0 | 0.002 |
| V1 vs. V2 | 91.0 vs. 92.0 | 0.802 |
| RV30Gy S1 vs. S2 | 64.0 vs. 63.0 | 0.0004 |
| V1 vs. V2 | 87.5 vs. 89.1 | 0.782 |
| RV35Gy S1 vs. S2 | 50.8 vs. 46.4 | <0.0001 |
| V1 vs. V2 | 83.5 vs. 83.5 | 0.922 |
| RV40Gy S1 vs. S2 | 30.0 vs. 36.6 | <0.0001 |
| V1 vs. V2 | 73.5 vs. 73.3 | 0.888 |
| RV45Gy S1 vs. S2 | 23.5 vs. 13.5 | <0.0001 |
| V1 vs. V2 | 60.0 vs. 57.5 | 0.789 |
| RV50Gy S1 vs. S2 | 6.0 vs. 12.5 | <0.0001 |
| V1 vs. V2 | 45.0 vs. 42.0 | 0.584 |
| RV55Gy S1 vs. S2 | 2.5 vs. 5.5 | <0.0001 |
| V1 vs. V2 | 30.5 vs. 37.5 | 0.669 |
| RV60Gy S1 vs. S2 | 1.0 vs. 3.0 | <0.0001 |
| V1 vs. V2 | 18.0 vs. 15.0 | 0.351 |

**Abbreviations:** BM bone marrow, RVxGy relative volume irradiated by xGy, S1 sternum of group1, S2 sternum of group2, V1 vertebra body of group1, V2 vertebra body of group2

**Figures**
Figure 1

Delineation on cross-sectional (a,b) and sagittal planes (c,d) CT. b and d shows the isodose line of target. Structures included tumor PTV (green), GTV (red), vertebra body BM (yellow) and sternum BM (blue).

Figure 2

Kaplan-Meier curves showing overall survival between group1 (green line) and group2 (blue line) before (left) and after (right) Propensity score matching.
Figure 3

The left shows data distribution of ALC2 in patients with tumor location in each group. The right shows the differences of ALC2 in patients with tumor location in each group by pairwise comparison. 1-Cervical EC; 2-Upper thoracic EC; 3-Middle thoracic EC; 4-Lower thoracic EC.

Figure 4

DVH of sternum BM(two red line) and vertebra body BM(two green line) of two groups after Propensity score matching,four solid line is the mean values of each groups.